| Literature DB >> 34345752 |
Nathalie L Maitre1,2,3, Kristen L Benninger1, Mary Lauren Neel1, Jennifer A Haase2, Lindsay Pietruszewski1, Katelyn Levengood1, Kathleen Adderley1, Nancy Batterson1, Kaleigh Hague1, Megan Lightfoot1, Sarah Weiss3, Dennis J Lewandowski1, Heather Larson4.
Abstract
INTRODUCTION: Neurodevelopmental surveillance is critical for high-risk infants following neonatal intensive care discharge and is traditionally performed in-person. COVID-19 interruption of regular surveillance necessitated a rapid development of telehealth models for effective and standardized care.Entities:
Year: 2021 PMID: 34345752 PMCID: PMC8322542 DOI: 10.1097/pq9.0000000000000439
Source DB: PubMed Journal: Pediatr Qual Saf ISSN: 2472-0054
Fig. 1.Active implementation framework for telehealth. PDSA, plan-do-study-act.
Fig. 2.Schedule of standardized high-risk infant follow-up visits with assessments. Bayley, Bayley Scales of Infant and Toddler Development; CBCL, Child Behavior Checklist; ITSP, Infant Toddler Sensory Profile; PLS, Preschool Language Scales; PDMS, Peabody Developmental Motor Scales; TIMP, Test of Infant Motor Performance.
Fig. 3.Telehealth value added analysis for the 3- to 4-month standardized visit. A and B, First visit process flow was mapped in swim lanes corresponding to multidisciplinary provider types. Then, a value-added analysis was performed from the parent/patient dyad’s perspective. Value-Added process steps met the following criteria: (1) transformed care in a way that moved it closer to its final state; (2) the step was unique and did not represent rework to correct previous steps performed incorrectly; and (3) the parent cared that the step was performed to achieve a successful visit and be willing to pay for the step. If the step did not meet all criteria in the affirmative it was not a Value-Added step, but was classified as business value-added (failed to meet parent willingness to pay for the step, but must be completed to comply with regulations or meet a business requirement) or non–value-added (fails to meet either other category and is considered waste). C, After value-added analysis, process improvements resulted in a 90% decrease in waste to the parent/patient dyad.
Fig. 4.Balancing Measures. A, Missed visits represent the percentage of patients who did not show for their visits compared to all scheduled visits, with the goal being 0%. This excludes patients who called to cancel 48 hours in advance. B, Provider efficiency represents the percentage of templated patient-visit slots per provider and per clinic half-day with the goal number being 4.5 or 100% (equivalent to 9 high complexity visits per day). Efficiency is influenced positively by scheduling providers to maximum capacity and negatively by cancelations that occur within 48 hours and cannot be replaced by waitlisted patients.
Primary Outcome: Parent Satisfaction with Telehealth Visits (N = 43)
| Strongly Agree | Agree | Neutral | Disagree | Strongly Disagree | NA | |
|---|---|---|---|---|---|---|
| Zoom was easy to use | 28 (65.1) | 13 (30.2) | 1 (2.3) | 1 (2.3) | 0 (0.0) | 0 (0.0) |
| The videoconferencing sessions were helpful | 28 (65.1) | 13 (30.2) | 1 (2.3) | 1 (2.3) | 0 (0.0) | 0 (0.0) |
| The nurse asked about my concerns | 31 (72.1) | 11 (25.6) | 0 (0.0) | 1 (2.3) | 0 (0.0) | 0 (0.0) |
| The visit with the doctor/nurse practitioner was helpful to understand how my child is doing | 26 (60.5) | 16 (37.2) | 0 (0.0) | 1 (2.3) | 0 (0.0) | 0 (0.0) |
| The visit with the therapist was helpful to understand how my child is doing | 17 (39.5) | 12 (27.9) | 8 (18.6) | 1 (2.3) | 0 (0.0) | 5 (11.6) |
| I like the procedures used during the visit | 20 (46.5) | 16 (37.2) | 7 (16.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| I felt well supported by the telehealth team despite the distance | 31 (72.1) | 10 (23.3) | 1 (2.3) | 1 (2.3) | 0 (0.0) | 0 (0.0) |
| I would recommend the telehealth visit to other families | 24 (55.8) | 15 (34.9) | 0 (0.0) | 4 (9.3) | 0 (0.0) | 0 (0.0) |
| I am satisfied with the overall quality of the telehealth visit | 26 (60.5) | 14 (32.6) | 1 (2.3) | 2 (4.7) | 0 (0.0) | 0 (0.0) |
Data are n (%), percentages may not add up to 100 because of rounding.
NA, not applicable.
Visit Comparison During COVID-19 and Corresponding 2019 Period
| Telehealth, N = 97 | In Person, N = 97 | ||
|---|---|---|---|
| Visit characteristics | |||
| Corrected age at visit, months, mean ± SD | 7.2 ± 7.6 | 7.2 ± 7.4 | 0.962 |
| Prematurity, N (%) | 55 (56.7) | 55 (56.7) | >0.99 |
| HIE, N (%) | 4 (4.1) | 4 (4.1) | >0.99 |
| IUGR, N (%) | 9 (9.3) | 9 (9.3) | >0.99 |
| NAS, N (%) | 20 (20.6) | 20 (20.6) | >0.99 |
| Other, N (%) | 9 (9.3) | 9 (9.3) | >0.99 |
| Primary outcome | |||
| No. high-risk for CP classifications or CP diagnoses, N (%) | 12 (12.4) | 10 (10.3) | 0.651 |
| Process metrics | |||
| Standard visit elements | |||
| HINE, performed/required (%) | 77/83 (92.8) | 79/86 (91.9) | 0.824 |
| GMA, performed/required (%) | 48/53 (90.6) | 42/51 (82.4) | 0.220 |
| Developmental assessments, performed/required (%) | 73/77 (94.8) | 85/89 (95.5) | 0.833 |
| Number subspecialty referrals made | 76 | 52 | 0.053 |
| Number diagnostic procedures ordered | 6 | 12 | 0.245 |
| Number prescriptions written | 10 | 5 | 0.181 |
*P based on group-level ANOVA.
†P based on Pearson’s chi-square.
HIE, hypoxic ischemic encephalopathy; IUGR, intrauterine growth restriction; NAS, neonatal abstinence syndrome.